E. Yu. Gubareva

6 ta ish

Samara State Medical University

1. International register “Dynamics analysis of comorbidities in SARS-CoV-2 survivors” (AKTIV) and the register “Analysis of hospitalizations of comorbid patients infected during the second wave of SARS-CoV-2 outbreak” (AKTIV 2)

   G. P. Arutyunov, E. I. Tarlovskaya, A. G. Arutyunov +97

   MaqolaOAOchiq kirish20215 iqtibos

   ABIABI:AkademIndex/2026.other.225825

2. Clinical features of post-COVID-19 period. Results of the international register “Dynamic analysis of comorbidities in SARS-CoV-2 survivors (AKTIV SARS-CoV-2)”. Data from 6-month follow-up

   G. P. Arutyunov, E. I. Tarlovskaya, A. G. Arutyunov +96

   MaqolaOAOchiq kirish20213 iqtibos

   ABIABI:AkademIndex/2026.other.1043652

3. Analysis of influence of background therapy for comorbidities in the period before infection on the risk of the lethal COVID outcome. Data from the international ACTIV SARS-CoV-2 registry («Analysis of chronic non-infectious diseases dynamics after COVID-19 infection in adult patients SARS-CoV-2»)

   E. I. Tarlovskaya, A. G. Arutyunov, А. О. Конради +97

   MaqolaOAOchiq kirishLong-Term Effects of COVID-19Kardiologiia20211 iqtibos

   ABIABI:AkademIndex/2021.article.000346

4. The impact of BMI on the course of the acute SARS-COV-2 infection and the risks that emerge during the first year after the hospital discharge. Subanalysis evidence of the AKTIV and AKTIV 2 registries

   A. G. Arutyunov, E. I. Tarlovskaya, G. R. Galstyan +97

   MaqolaOAOchiq kirish20231 iqtibos

   ABIABI:AkademIndex/2026.other.1043653

5. Regional differences in presentation characteristics, use of treatments and outcome of patients with cardiogenic shock: Results from multicenter, international registry

   Michal Pazderník, Mario Gramegna, Allan Böhm +19

   MaqolaOAOchiq kirishMechanical Circulatory Support DevicesBiomedical Papers20210 iqtibos

   ABIABI:AkademIndex/2021.article.001052

6. Clinical features of post-COVID period. Results of an International Register "Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors (ACTIV SARS-CoV-2)" (12-month follow-up)

   G. P. Arutyunov, E. I. Tarlovskaya, A. G. Arutyunov +97

   MaqolaOAOchiq kirish20220 iqtibos

   ABIABI:AkademIndex/2022.article.030976